The current financial score of Celldex Therapeutics Inc is 5.71. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 22.00K, representing a year-over-year decrease of 96.99%, while its net profit experienced a year-over-year decrease of 29.86%.
The current valuation score of Celldex Therapeutics Inc is 8.02. Its current P/E ratio is -9.13, which is -38.76% below the recent high of -5.59 and -116.75% above the recent low of -19.80.
The current earnings forecast score of Celldex Therapeutics Inc is 8.53. The average price target is 58.38, with a high of 100.00 and a low of 38.00.
The current price momentum score of Celldex Therapeutics Inc is 3.52. Currently, the stock price is trading between the resistance level at 41.79 and the support level at 36.51, making it suitable for range-bound swing trading.
The current institutional shareholding score of Celldex Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 96.30%, representing a quarter-over-quarter decrease of 26.99%. The largest institutional shareholder is Ken Fisher, holding a total of 985.68K shares, representing 0.01% of shares outstanding, with 25.72% increase in holdings.
The current risk assessment score of Celldex Therapeutics Inc is 7.17. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.